[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
August 10, 2011

European Drug Agency Under Fire

JAMA. 2011;306(6):593-595. doi:10.1001/jama.2011.1102

The European Medicines Agency (EMA), the European counterpart to the US Food and Drug Administration (FDA), has lately experienced a number of blows to its reputation, coming under fire over policies related to the accessibility of unpublished clinical trial data in its database, as well as conflicts of interest for its officials. The controversy underscores long-standing concerns that the inaccessibility of unpublished data from clinical trials sponsored by pharmaceutical companies undermines appropriate evaluation of the relative benefits and risks of a medication.

First Page Preview View Large
First page PDF preview
First page PDF preview